Active poly-GA vaccination prevents microglia activation and motor deficits in a C9orf72 mouse model

Qihui Zhou1,2,†, Nikola Mareljic1,†, Meike Michaeisen1, Samira Parhizkar3, Steffanie Heindl4, Brigitte Nuscher3, Daniel Farny1, Mareike Czuppa1, Carina Schludi1, Alexander Grafe2, Stefan Krebs5, Helmut Blum5, Regina Feederle1,2,6,†, Stefan Roth2,4, Christian Haass1,2,3,†, Thomas Arzberger1,2,7,8, Arthur Liesz2,4,† & Dieter Edbauer1,2,9,†

Abstract

The C9orf72 repeat expansion is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD). Non-canonical translation of the expanded repeat results in abundant poly-GA inclusion pathology throughout the CNS. (GA)149-CFP expression in mice triggers motor deficits and neuroinflammation. Since poly-GA is transmitted between cells, we investigated the therapeutic potential of anti-GA antibodies by vaccinating (GA)149-CFP mice. To overcome poor immunogenicity, we compared the antibody response of multivalent ovalbumin-(GA)10 conjugates and pre-aggregated carrier-free (GA)15. Only ovalbumin-(GA)10 immunization induced a strong anti-GA response. The resulting antisera detected poly-GA aggregates in cell culture and patient tissue. Ovalbumin-(GA)10 immunization largely rescued the motor function in (GA)149-CFP transgenic mice and reduced poly-GA inclusions. Transcriptome analysis showed less neuroinflammation in ovalbumin-(GA)10-immunized poly-GA mice, which was corroborated by semiquantitative and morphological analysis of microglia/macrophages. Moreover, cytoplasmic TDP-43 mislocalization and levels of the neurofilament light chain in the CSF were reduced, suggesting neuroaxonal damage is reduced. Our data suggest that immunotherapy may be a viable primary prevention strategy for ALS/FTD in C9orf72 mutation carriers.

Keywords amyotrophic lateral sclerosis; C9orf72; frontotemporal dementia; immunotherapy; neurodegeneration

Subject Categories Immunology; Neuroscience

Introduction

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) cases with C9orf72 mutation show characteristic nuclear foci of the sense and antisense repeat RNA [(G4C2)n and (C4G2)n] as well as neuronal inclusions resulting from non-canonical translation of the repeat RNA in all reading frames (DeJesus-Hernandez et al, 2011; Renton et al, 2011; Ash et al, 2013; Mori et al, 2013; Edbauer & Haass, 2016). In addition, C9orf72 protein levels are reduced due to impaired transcription of the expanded allele (Frick et al, 2018). Gain-of-function mechanisms are likely the main drivers of C9orf72 disease because C9orf72 knockout mice develop mainly alterations of the peripheral immune system, reminiscent of systemic lupus erythematosus (Atansio et al, 2016; Jiang et al, 2016). None of the C9orf72-specific pathologies correlate robustly with TDP-43 pathology or neurodegeneration suggesting synergistic and/or non-cell autonomous effects are crucial (Mackenzie et al, 2013, 2015; Schludi et al, 2015; DeJesus-Hernandez et al, 2017). So far, toxicity due to expression of individual dipeptide repeat (DPR) proteins has been studied most extensively. Poly-GA is the most abundant DPR species in patients and poly-GA expression has the strongest effect on TDP-43 phosphorylation and aggregation in primary neurons and mice, which correlates best with neurodegeneration in patients (Khosravi et al, 2017; Lee et al, 2017; Schludi et al,
2017; Nonaka et al., 2018). In addition, poly-GA mouse models show motor deficits and neuroinflammation (Zhang et al., 2016; Schludi et al., 2017). Large biomarker studies and neuropathological reports from rare presymptomatic C9orf72 cases suggest that all pathognomonic features of the disease are present decades before the onset of symptoms in the absence of widespread TDP-43 aggregation and neuron loss (Vatsavayai et al., 2016; Gendron et al., 2017; Lehner et al., 2017). These prodromal changes likely initiate a slow disease cascade with neuroinflammation and TDP-43 aggregation that may eventually become independent of the initial trigger (Edbauer & Haass, 2016). Thus, targeting the C9orf72-specificopathomechanisms early will be essential for effective disease prevention or therapy.

Targeting cytoplasmic Tau aggregates by active and passive immunotherapy has shown promise in rodent models of Alzheimer’s disease (AD), and effects on both intracellular and (unconventionally secreted) extracellular Tau have been discussed (Congdon & Sigurdsson, 2018). For example, intraventricular infusion of Tau antibodies reduced the aggregate burden and improved cognitive deficits in mice (Yanamandra et al., 2013). Moreover, active immunization targeting the Tau oligomerization domain was beneficial in a rat model and is being investigated in a phase 2 clinical trial (Kontsekova et al., 2014; Novak et al., 2017, 2018a; Jadhav et al., 2019). Unfortunately, the more advanced clinical trials with active and passive immunotherapy targeting extracellular Aβ aggregates in patients with AD were largely disappointing despite great promise from mouse models (Schenk et al., 1999; Sevigny et al., 2016). The key insights from these studies are as follows: (i) Antibodies can penetrate the blood–brain barrier at low levels that may be sufficient to affect the target (Schenk et al., 1999; Orgogozo et al., 2003; Landen et al., 2017). (ii) Clearance of Aβ load correlates with the antibody titer (Sevigny et al., 2016). (iii) Unwanted T-cell responses to active vaccination caused severe meningoencephalitis in a subset of AD patients but may be prevented by careful choice of the epitope (Schenk et al., 1999; Orgogozo et al., 2003; Axelsen et al., 2011). (iv) Limited cognitive improvement despite efficient clearance of Aβ in patients suggests disease mechanisms change and therapy should be started very early, maybe even in the prodromal phase, which is difficult in a mainly sporadic disease (Landen et al., 2017).

The common C9orf72 mutation offers a unique opportunity for preventive therapy in ALS/FTD, but immunotherapy has not been tested in vivo. We and others have shown that cytoplasmic DPR proteins are transmitted between cells (Westergard et al., 2016; Zhou et al., 2017; Nonaka et al., 2018). After showing that monoclonal antibodies inhibit poly-GA aggregation and seeding from patient brain extracts in vitro (Zhou et al., 2017), we asked whether DPR immunotherapy would ameliorate DPR pathology and related deficits in an established poly-GA mouse model (Schludi et al., 2017). To this end, we tested different peptide formulations and analyzed the effects on motor deficits, poly-GA, TDP-43, neuronal damage, and neuroinflammation in vaccinated mice.

### Results

**Ova-(GA)10 elicits strong antibody response in mice**

To induce anti-GA antibody production in vivo, we immunized wild-type and GA-CFP mice prior to the onset of motor deficits with poly-GA peptides in incomplete Freund’s adjuvant. Since poly-GA is expected to be poorly immunogenic, we used ovalbumin as an immunogenic carrier molecule (Ova-(GA)10) that also may keep the aggregation-prone poly-GA soluble. In addition, we used a carrier-free self-aggregating (GA)15 as immunogen (Chang et al., 2016). We started the immunization at 8 weeks of age and continued with boosting in 4-week intervals (Fig 1A) while subjecting the mice to weekly behavioral tests (see Fig 2). Immunization did not increase lethality or cause other obvious negative side effects in wild-type or transgenic mice (Fig EV1). Regardless of the immunization regimen, the mice gained weight steadily (Fig EV1A). To quantify the humoral immune response, we collected serum from all mice 1 week before initial immunization and 1 week after each immunization. We quantified the anti-GA IgG immune response in the mouse sera using an ELISA with GST-(GA)15 as antigen and a mouse monoclonal anti-GA antibody as reference standard. Surprisingly, (GA)15 induced no detectable antibody response as compared to the control mice that received PBS in adjuvant even after multiple boosting. In contrast, Ova-(GA)10 induced a strong antibody response increasing up to ~400 μg/ml after the fourth boosting in both wild-type and GA-CFP transgenic mice (Fig 1B). Despite the strong immune response, distribution of splenic lymphocyte population was not affected in immunized mice (Fig EV1B).

The Ova-(GA)10 antiserum specifically detected poly-GA in transgenic HEK293 cells by immunoblotting and immunofluorescence (Fig EV2A–C). We used the mouse antisera for immunohistochemistry in cerebellar sections from a C9orf72 patient and a healthy control (Fig 1C). The Ova-(GA)10 antiserum specifically detected the pathognomonic dot-like inclusions in the molecular layer of the cerebellum (Fig 1C and D). We confirmed the specificity of Ova-(GA)10 antiserum by blocking experiment using recombinant GST-(GA)15 (Fig 1E) and double immunofluorescence using a rabbit anti-GA antibody (Fig EV3). Thus, our prime-boosting regimen using Ova-(GA)10 induces high levels of specific anti-GA antibodies without apparent side effects in mice.

**Ova-(GA)10 immunization prevents motor deficits in GA-CFP mice by reducing poly-GA aggregation**

GA-CFP mice develop motor and coordination deficits starting at the age of 4 months (Schludi et al., 2017). To analyze the therapeutic effect of immunization, we assessed motor performance using weekly beam walk assay starting at 9 weeks of age before the onset of symptoms. From week 15, control-immunized GA-CFP mice (TG-PBS) needed significantly more time than wild-type mice to cross the beam consistent with our previous findings (Figs 2A and EV4). Occasionally, TG-PBS mice could not complete the beam walk task and dropped down, which was not observed in wild-type mice and hardly occurred in TG-Ova-(GA)10 mice (Fig 2B). Consistent with the lack of antibody response, (GA)15-immunized GA-CFP mice (TG-(GA)15) performed as poor as TG-PBS mice. In contrast, Ova-(GA)10-immunized GA-CFP mice (TG-Ova-(GA)10) initially developed motor deficits compared to wild-type littermates at week 17, but improved at later time points and performed close to wild-type level suggesting that a high antibody titer is required for the beneficial effect of immunization. Immunohistochemistry of the spinal cord confirmed the typical neuronal cytoplasmic poly-GA inclusion pathology in GA-CFP transgenic mice (Fig 2C; Schludi et al., 2017).
Figure 1.

A

Immunization

Blood sampling

7w  9w  13w  17w  21w  25w  29w

8w  12w  16w  20w  24w  28w



B

WT-PBS (n=11)

WT-Ova-(GA)10 (n=10)

WT-(GA)15 (n=9)

TG-PBS (n=10)

TG-Ova-(GA)10 (n=10)

TG-(GA)15 (n=10)



C

Anti-GA (1A12)  TG-PBS serum  TG-Ova-(GA)10 serum  TG-(GA)15 serum

Control

C9orf72



D

GA % neurons

ctr  C9  ctr  C9

Anti-GA (1A12)  TG-Ova-(GA)10) serum



E

Anti-GA (1A12)  TG-PBS serum  TG-Ova-(GA)10 serum  Blocking peptide

Control

C9orf72


Image-based quantification revealed reduced aggregate density in TG-Ova-(GA)10 mice compared to TG-PBS control (Fig 2D). This was further confirmed using a poly-GA immunoassay (Fig 2E). Consistent with the lack of antibody response and lack of any beneficial effect in the beam walk, (GA)15 immunization did not affect the abundance of poly-GA aggregates in both assays. Taken together, repeated Ova-(GA)10 immunization is an effective prevention strategy in GA-CFP mice.

Ova-(GA)10 immunization reduced neuronal damage, TDP-43 mislocalization, and microglia/macrophage activation in GA-CFP mice

To elucidate the mode of action, we performed unbiased RNA sequencing analysis on spinal cord from TG-PBS, TG-Ova-(GA)10 mice, and their respective wild-type control mice. Pairwise comparison revealed no significant difference between the wild-type groups, but 545 differentially expressed genes between TG-PBS vs. WT-PBS and 233 between TG-Ova-(GA)10 vs. TG-PBS using 1.5-fold change (log2 > 0.585) as cutoff (Datasets EV1–EV4). 210 genes differentially expressed in TG-PBS were significantly rescued in the immunized mice. Poly-GA expression triggered many immune pathways including production of multiple cytokines/chemokines. Ova-(GA)10 immunization attenuated several immune pathways, for example, induction of Ccl4, Gm, Tyrobp, and complement factors (Fig 3A and B, and Dataset EV1). Thus, we analyzed activated microglia/macrophages using Iba1 immunohistochemistry. Similar to our previous report, GA-CFP transgenic mice showed strong microglia/macrophage activation in the spinal cord compared to wild-type littermates (Fig 3C). Both the density of Iba1-positive microglia/macrophages and the area covered by Iba1 staining were strongly reduced in TG-Ova-(GA)10 mice (Figs 3C and D, and EV5A). Correspondingly, automated analysis of microglia/macrophage 3D morphology revealed significantly altered key features of microglial morphology (sphericity, number of branches) in TG-PBS mice compared to WT mice, which was significantly rescued in TG-Ova-(GA)10 mice (Fig EV5B–D).

Since poly-GA triggers modest TDP-43 phosphorylation and partial cytoplasmic mislocalization of TDP-43 (Khosravi et al, 2017; Lee et al, 2017; Schludi et al, 2017; Nonaka et al, 2018), we next analyzed the effect of immunization on the levels of cytoplasmic TDP-43 in the spinal cord (Figs 3E and EV5E). While TG-PBS showed a significant increase in cells with cytoplasmic TDP-43 compared to control animals, mice immunized with Ova-(GA)10 but not (GA)15 showed reduced levels of cytoplasmic TDP-43 compared to TG-PBS suggesting anti-GA antibodies reduce secondary TDP-43 pathology.

Finally, we analyzed the level of neurofilament light chain (NFL), which is as a biomarker for neuroaxonal damage in ALS and other diseases (Meeter et al, 2016; Feneberg et al, 2018; Khalil et al, 2018). Indeed, we observed significantly reduced level of NFL in CSF of TG-Ova-(GA)10 suggesting the attenuation of neuroaxonal damage in these mice (Fig 3F). Taken together, Ova-(GA)10 vaccination partially prevented neurodegeneration, reducing TDP-43 mislocalization and microglia/macrophage activation in poly-GA mice.

Discussion

We show that poly-GA vaccination is safe and effective in a C9orf72 mouse model. An immunogenic carrier protein such as ovalbumin can greatly enhance immunogenicity of poly-GA and can drive a high-level antibody response that would be difficult to maintain with regular intravenous injection of monoclonal antibodies. Presymptomatic poly-GA vaccination reduces inclusions and largely prevents TDP-43 mislocalization, neuroinflammation, neuroaxonal damage, and motor deficits in GA-CFP mice suggesting vaccination is a promising prevention strategy in the long prodromal phase of C9orf72 ALS/FTD.

Antigenicity and side effects

The humoral immune system has evolved to combat viruses and bacteria and strongly responds to other similar sized particles. This may explain why vaccination with aggregated full-length Aβ without carrier protein in the AN-1792 formulation was highly immunogenic (Schenk et al, 1999; Lee et al, 2005). We tested the antibody response using pre-aggregated (GA)15, which would avoid use of carrier proteins that may cause unwanted side effects. However, even repeated boosting did not trigger any antibody response and showed no beneficial effects on motor function and histopathology. Since previous immunizations with soluble GST-(GA)15 antigen resulted in only very weak antibody responses in rabbits (Mori et al, 2013), we covalently coupled (GA)10 to maleimide-activated ovalbumin resulting in a multivalent antigen (5:1–15:1 ratio) that we also used to generate monoclonal antibodies (Mackenzie et al, 2013). Indeed, immunization with Ova-(GA)10
Figure 2.
using an extended boosting regimen resulted in high antibody titers in GA-CFP as well as wild-type mice.

The high antibody titers of ~400 µg/ml would be difficult to maintain over prolonged time periods using intravenous injection of monoclonal antibodies, which typically results in 100–200 µg/ml serum levels that drop sharply within weeks in humans (Sevigny et al., 2016; Landen et al., 2017). Low antibody trough levels and development of anti-drug antibodies are known to limit the long-term efficacy of antibody therapy in oncology and inflammatory diseases (Mazor et al., 2014; Kverneland et al., 2018). For neurodegenerative disease, the poor delivery across the blood–brain barrier is rate-limiting. Antibody engineering can increase antibody delivery from ~0.05 to 0.5% (Yu et al., 2014). Thus, maintaining high antibody levels is likely superior to intermittent i.v. antibody administration even using the best available methods to enhance blood–brain barrier delivery.

The safety profile of life-long administration of highly immuno- genic carriers will need to be investigated before widespread application. We noticed no adverse effects such as T-cell infiltration or other signs of meningoencephalitis, but unfortunately experiments in mice cannot sufficiently predict the T-cell response in humans (Schenk et al., 1999; Orgogozo et al., 2003).

**Mode of action**

So far, active vaccination in neurodegenerative diseases has often served as an entry point for passive immunotherapy, but given a good safety profile, active vaccination would be ideal for prevention. Benefits of preventive vaccination have been first reported in Aβ mouse models (Schenk et al., 1999) and later in α-synuclein mice (Masliah et al., 2005) and Tau transgenic mice (Asuni et al., 2007; Boimel et al., 2010) and rats (Kontsekova et al., 2014). In contrast to the side effects of Aβ vaccination in humans, repeated active immunization with a peptide vaccine targeting Tau showed no adverse events in a phase 1 trials (Novak et al., 2017, 2018b). Cytoplasmic aggregates of Tau and α-synuclein have also been successfully targeted by antibodies, but the mode of action is still under debate (Masliah et al., 2011; Yanamandra et al., 2013; Games et al., 2014; El-Agnaf et al., 2017; Congdon & Sigurdsson, 2018). Antibodies may prevent seeding and cell-to-cell transmission as shown for Tau (Rajamohamedsait et al., 2017; Albert et al., 2019).

Our data that anti-GA vaccination predominantly reduces microglia-mediated neuroinflammation suggest that the resulting antibodies may bind and neutralize secreted poly-GA. We had previously shown that monoclonal anti-GA antibodies can reduce poly-GA uptake and seeding of patient brain extracts (Zhou et al., 2017). Alternatively, antibody uptake may enhance lysosomal or proteasomal degradation, for example, via the intracellular Fc-receptor TRIM21 (Mallery et al., 2010; McEwan et al., 2017), which may reduce neuronal stress signals that trigger harmful microglia/macrophage activation. Our transcriptome analysis confirms that transgenic poly-GA expression induces neuroinflammation and Ova-(GA)10 immunization attenuated several immune pathways. Our finding that anti-GA vaccination also rescues the level of cytoplasmic TDP-43 suggests that targeting a single component may be sufficient to delay or even stop disease progression in C9orf72-associated ALS/FTD. Importantly, TDP-43 aggregation has also been linked to microglia activation (Swarup et al., 2011; Zhao et al., 2015).
Figure 3.
Prevention vs. therapy

Familial variants of neurodegenerative diseases offer the unique chance for true disease prevention until somatic gene editing may allow a genetic cure in the future. With the rise of genetic testing in ALS/FTD patients, an increasing number of relatives become aware of their high disease risk and are eagerly looking for therapeutic options. Preventive treatment with antisense oligonucleotides ameliorated disease in C9orf72 mouse models but would require regular intrathecal injection (Jiang et al., 2016; Gendron et al., 2017). Moreover, reaching a sufficient dose throughout the human brain will be far more difficult than targeted therapy of the spinal cord in spinal muscular atrophy (Chiriboga et al., 2016). Although current poly-GA models suggest that poly-GA is not sufficient to mimic the complete pathophysiology of ALS/FTD in mice (Zhang et al., 2016; Schlu di et al., 2017), targeting poly-GA may be sufficient to prevent ALS/FTD, which should be tested in C9orf72 BAC mice in the future (Jiang et al., 2016; Liu et al., 2016). Importantly, immunotherapy reduces poly-GA-dependent TDP-43 pathology in our mouse model. Taken together, active vaccination is a promising approach to reduce disease severity or even prevent ALS and FTD in people carrying the C9orf72 mutation and highlights the importance poly-GA-induced neuronal damage and microglia/macrophage activation.

Materials and Methods

Mice and immunization

(GA)_{1,49}-CFP-expressing transgenic (TG) mice from C57BL/6J background have been characterized in detail (Schlu di et al., 2017). For genotyping, mice genomic DNA was prepared using Hot Sodium Hydroxide and Tris (HotSHOT) method as described previously (Truett et al., 2000). Genotyping PCR was performed using the primers 5′-tcagggcagctaccatat-3′ and 5′-gttcgagctagttgtc-3′. The presence of the full-length transgene was confirmed with PCR amplification (Expand Long Template PCR System, Roche, 5×).

Immunization followed the protocol for generation of mouse monoclonal anti-GA antibodies (Mackenzie et al., 2013) with additional boosting immunizations (prime-booster regimen as in Fig 1A). For the first immunization, 40 μg Ova-(PEG)_{3}-(GA)_{10} or (GA)_{15} (Peptide Speciality Laboratories GmbH, Heidelberg) was mixed with 5 nmol CpG ODN 1668 oligonucleotide (Enzo Life Science) in 200 μl PBS and 250 μl incomplete Freund’s adjuvant and injected half-half intraperitoneally (i.p.) and subcutaneously (s.c.) at 8 weeks of age. The control group (PBS) received injection of 200 μl PBS and 250 μl incomplete Freund’s adjuvant together with 5 nmol CpG ODN 1668. For the five consecutive booster immunizations, 40 μg Ova-(PEG)_{3}-(GA)_{10} or (GA)_{15} was mixed with 5 nmol CpG ODN 1668 in 500 μl PBS and was injected half-half i.p. and s.c. at weeks 12, 16, 20, 24, and 28 (see Fig 1A). The control group (PBS) received injection of 495 μl PBS together with 5 nmol CpG ODN 1668. Nine to 11 animals with similar gender ratio per group were included in the study.

Animal handling and animal experiments were performed in accordance with institutional guidelines approved by local animal laws and housed in standard cages in pathogen-free facility on a 12-h light/dark cycle with ad libitum access to food and water.

Beam walk test

Mice were placed on a wooden beam (round surface, length 58 cm, diameter 8 mm) and had 1 min to cross the beam. The measurement was completed when the mice reached the end of the stick, they dropped down, or the time ran out. For the statistical analysis, failed attempts were set to 1 min. The experimenters were blind to the genotype, and trials were video-documented for the analysis. Starting at the age of 9 weeks old, the assay was repeated weekly with two consecutive trials. Results from two consecutive weeks (four total runs) were averaged for analysis.

Serum and CSF collection and tissue harvesting

At 7, 9, 13, 17, 21, 25, and 29 weeks of age, blood was taken and incubated 15 min at room temperature. Serum was collected by centrifugation (13,000 g for 10 min at 4°C) and snap-frozen on dry ice. After the behavior experiments, animals were anesthetized by intraperitoneal administration of medetomidine (0.5 mg/kg) + midazolam (5 mg/kg) + fentanyl (0.05 mg/kg). Cerebrospinal fluid (CSF) was collected from the cisterna magna according to the previously published methods (Schelle et al., 2017). Transcardial perfusion was performed with cold phosphate-buffered saline (PBS). Tissue was either stored at −80°C for biochemical analysis or formalin-fixed for 24 h for immunohistochemistry analysis. For spinal cord tissue, an additional decalcification step with 5% formic acid for 48 h after formalin fixation was performed. For the microglia morphology study, thoracic segments T1–T7 were dissected after formalin fixation.

Primary antibodies

Antibodies to poly-GA (1:500, Proteintech, 24492-1-AP), GFP (1:1,000, Clontech, 632592), Ibα1 (1:500, Wako, 091-19741), TDP-43 (1:500, Proteintech, 10782-2-AP), calnexin (1:3,000, Enzo Life Science, SPA-860F), CD3 (eBioscience, 17A2), anti-CD4 (clone: RM4-5, eBioscience), CD8 (eBioscience, 53-6.7), CD19 (eBioscience, eBio1D3), CD45 (eBioscience, 30-F11), and CD11b (eBioscience, M1/70) are commercially available. In addition to our previous anti-GA clone 5F2 (purified mouse monoclonal, biotinylated 1:1,000, Sulfo-Tagged 10 ng/ml) used for immunoassay, we used clone 1A12 established from the same immunization (Mackenzie et al., 2013), which shows superior staining specificity (mouse monoclonal, IgG1, WB 1:50, IHC 1:100).

Antibody titer ELISA

To measure the antibody titer, Nunc MaxiSorp™ flat-bottom 96-well plates were incubated with recombinant GST-(GA)_{15} produced in E. coli (Mori et al., 2013) in PBS overnight at 4°C. After 1 h incubation in blocking solution (1% BSA, 0.05% Tween 20 in PBS), samples (predilute 1:100 or 1:100,000) were added for 1 h. After three washes with 0.05% Tween 20 in PBS, anti-GA antibodies were detected with anti-mouse HRP. 3′,3′,5′-Tetramethylenediamine (Sigma) was used as chromogenic substrate. After stopping the
reaction with 2M H₂SO₄, the absorbance was read at 450 nm. Serial dilution of purified mouse monoclonal anti-GA clone 1A12 was used to generate a standard curve for absolute quantification. Two technical replicates were measured for each sample.

DNA constructs, Cell culture, transfection, immunofluorescence, and immunoblot

ATG-initiated epitope-tagged synthetic expression constructs for GA₁₁₁-GFP, GA₁₄₉-myc, GP₁₁₁-GFP, GFP-GR₁₄₉, PA₁₁₁-GFP, and PR₁₁₁-GFP in pEF6/V5-His vector were described previously (May et al., 2014; Schludi et al., 2015; Zhou et al., 2017).

HEK293FT cells were transfected using Lipofectamine 2000 (Thermo Scientific) according to the manufacturer’s instruction and cultivated with DMEM containing 10% FCS and penicillin/streptomycin. For immunofluorescence, cells were fixed with 4% paraformaldehyde and 4% sucrose for 10 min and stained with the indicated antibodies in GDB buffer (0.1% gelatin, 0.3% Triton X-100, 450 mM NaCl, 16 mM sodium phosphate pH 7.4). Images were taken using an LSM810 confocal laser scanning system (Carl Zeiss) with 40× or 63× oil immersion objectives.

For immunoblotting, samples were prepared as described previously (May et al., 2014) and separated on 10–20% tricine protein gels (Thermo Fisher) and transferred to PVDF membranes. Membranes were blocked with 0.02% t-block in PBS with 0.2% Triton X-100 for 1 h and then incubated with the respective antibodies overnight at 4°C. After washing with TBST, membranes were incubated with anti-mouse HRP antibody for 1 h at RT. After washing with TBST, signals were developed with ECL (Thermo) and detected with Super RX Fuji medical X-Ray film (Fujifilm).

Transcriptome analysis

We isolated RNA from thoracic segments T8–T13 of spinal cord from WT and GA-CFP mice immunized with PBS or OVA-(GA)₁₀ using Direct-zol RNA MicroPrep (Zymo Research), generated libraries using the mRNA SENSE kit V2 from Lexogen (Vienna, Austria) essentially according to the manufacturer’s instructions and performed 100 bp single-read sequencing on a Illumina HiSeq1500 (Illumina, San Diego CA, USA). Reads were aligned to the mouse genome (mm10) using STAR (Version 2.5.2b-0) (Dobin et al., 2013) supplied with the UCSC gene models obtained from iGenomes. Count tables were generated using HTSeq-count (Version 1.0.0), and differential expression for WT-OVA vs. WT-PBS, TG-PBS vs. WT-PBS, and TG-OVA vs. TG-PBS was performed using DESeq2 (Version 2.11.40.6) (Love et al., 2014) in Galaxy (full expression analysis is presented in Datasets EV2–EV4; Aftgan et al., 2018). Genes with adjusted P-values below 0.05 and absolute log₂-fold change higher than 0.585 (1.5-fold change) were used for gene ontology analysis using clusterProfiler (version 3.12) (Yu et al., 2012). A manual selection of meaningful and highly significantly enriched GO categories is shown in Fig 3A. The full data are presented in Dataset EV1.

Flow cytometry analysis

Fresh spleens were transferred to Hank’s balanced salt solution, homogenized and filtered through 40-μm cell strainers. Erythrocytes in spleens were lysed using isotonic ammonium chloride buffer. Splenocytes were stained according to the manufacturer’s protocol and were measured on a BD FACSVerse flow cytometer (BD Biosciences) and analyzed using FlowJo 10.4 software (Treestar).

Poly-GA immunoassay

The poly-GA immunoassay was performed to measure insoluble poly-GA in the spinal cord of GA-CFP mice as described previously with modifications (Schludi et al., 2017). Mouse spinal cord samples were homogenized in 1 ml of RIPA buffer (137 mM NaCl, 20 mM Tris pH 7.5, 10% glycerine, 1% Triton X-100, 0.5% Na-deoxycholate, 0.1% SDS, 2 mM EDTA, protease and phosphatase inhibitors, benzonase nuclease) using homogenizer (Precellys). Samples were incubated with shaking at 4°C for 20 min and centrifuged at 13,000 g for 10 min at 4°C. To avoid cross-contamination between soluble and insoluble fractions, pellets were resuspended in 1 ml RIPA, re-homogenized, and re-centrifuged. The RIPA-insoluble pellets were sonicated in RIPA buffer containing 3.5 M Urea (URIPA), and protein concentration was determined by Bradford assay. Streptavidin Gold multi-array 96-well plates were incubated with biotinylated anti-GA clone 5F2 overnight at 4°C and blocked with 1% BSA, 0.05% Tween 20 in PBS for 1 h. Equal amounts of samples were added in duplicate wells for 1.5 h, followed by 1.5 h incubation with the secondary MSD-labeled α-GA clone 5F2. Serial dilution of recombinant GST-(GA)₁₅ in blocking buffer was used to generate a standard curve. The intensity of emitted light upon electrochemical stimulation was measured using the MSD QuickPlex 520, and the background was corrected by the average response obtained from blank wells.

Microglia morphology analysis

Automated morphological analysis of microglia in spinal cord was reported previously (Heindl et al., 2018). Free floating staining of 100-μm-thick vibratome sections of spinal cord were blocked and incubated with anti-Iba1 for 36 h. After intensive wash, sections were incubated with secondary antibody anti-rabbit coupled to Alexa Fluor 594. Nuclei were stained with DAPI. Sections were mounted with VECTASHIELD® Hardset™ Antifade Mounting Medium. Images were acquired using a Zeiss confocal microscope with 40× magnification (objective: EC Plan-Neofluar 40×/1.30 Oil DIC M27) with an image matrix of 1,024 × 1,024 pixel, a pixel scaling of 0.2 × 0.2 μm, and a depth of 8 bit. Confocal images were collected in Z-stacks with a slice distance of 0.4 μm. Images were processed using a MATLAB implemented processing pipeline as described previously.

Patient tissue, immunohistochemistry, and quantitative analysis

All patient materials were provided by the Neurobiobank Munich and Ludwig-Maximilians-University (LMU) Munich and approved by the ethical committee of Ludwig-Maximilians-University (LMU) Munich. All subjects and the experiments were confirmed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report. Informed consent was obtained from all subjects.
The paper explained

Problem
The poor results of clinical trials in amyotrophic lateral sclerosis (ALS) and other neurodegenerative disease suggest we still lack a basic understanding of causality. The key disease mechanisms may change during disease progression, and halting further neuron loss has not been achieved and may not even improve the symptoms and survival. About 10–20% of patients with ALS and 40–50% of patients’ frontotemporal dementia (FTD) show a Mendelian pattern of inheritance and with the advent of genetic testing of patients many relatives at risk ask for preventive options. The most common known mutation found in about ~10% of patients in Europe and the United States is a \((G_4C_2)_n\) repeat expansion in the non-coding region of C9orf72. Sense and antisense repeat transcripts are translated in all reading frames into five aggregating dipeptide repeat (DRP) proteins that form predominantly neuronal cytoplasmic inclusions that are detectable many years prior to disease onset. In animal models, gain-of-function mechanisms are clearly the main drivers of pathogenesis, but it is unclear what ultimately triggers symptomatic disease characterized by regional TDP-43 pathology and neurodegeneration. We have previously shown that DRPs are transmitted between cells and asked whether antibody therapy that potentially target extracellular DPR species could be used for prevention or therapy of C9orf72 ALS/FTD.

Results
We immunized a transgenic mouse model expressing the most abundant DRP protein, poly-GA, using two different vaccine formulations to induce anti-GA antibodies in vivo. Only ovalbumin-coupled \((GA)_{15}\) but not \((GA)_{10}\) induced a high-titer antibody response (> 400 μg/ml) in a prime/boost regimen without side effects. Treated mice showed less poly-GA aggregation and cytoplasmic mislocalization of TDP-43. Importantly, vaccination with Ova-(GA)\(_{15}\) largely prevented motor symptoms and microglia/macrophage activation in vivo. In addition, TDP-43 mislocalization and levels of neurofilament light chain, a biomarker for neuroaxonal damage, were reduced by Ova-(GA)\(_{15}\) immunization suggesting improved neuronal health.

Impact
We show that poly-GA immunotherapy may prevent onset of ALS and FTD in C9orf72 mutation carriers by inhibiting protein aggregation and microglia/macrophage activation. Coupling poly-GA peptides with a carrier protein greatly enhanced immunogenicity of poly-GA leading to very high antibody titers that would be difficult to maintain with regular i.v. administration. Early treatment of C9orf72 mutation carriers with a safe and effective poly-GA vaccine may prevent transition from the prodromal DPR-dominated disease stage to the symptomatic disease associated with TDP-43 pathology. In addition, our data support development of passive immunotherapy with monoclonal antibodies.

Data availability
The datasets produced in this study are available in the following database: RNA-seq data: Gene Expression Omnibus GSE138413 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138413).

Acknowledgements
We thank Bahram Khosravi, Kai Schlepckow, Sabina Tahirovic, and Xianyuan Xiang for critical comments to the manuscript. This work was supported by NOMIS Foundation and the Hans und Ilse Breuer Foundation (C.H. and D.E.), the Munich Cluster of Systems Neurology (SyNergy) (D.E., Q.Z., A.L., C.H. R.F.), and the European Community’s Health Seventh Framework Programme under grant agreement 617198 (DPR-MODELS) (D.E.).

Author contributions
QZ and NM designed, performed, and interpreted the immunization study with technical help from MM and DF. SP collected CSF samples from mice. BN, MC, and CS performed and interpreted the biomarker studies. CH supervised biomarker study and provided technical resources. SH, SR, and BN, MC, and CS performed and interpreted the biomarker studies. CH performed and interpreted the immunization study with technical help from MM and DF. SP collected CSF samples from mice. BN, MC, and CS performed and interpreted the biomarker studies. CH supervised biomarker study and provided technical resources. SH, SR, and BN, MC, and CS performed and interpreted the biomarker studies.
Conflict of Interest
Q.Z., N.M., and D.E. are inventors on a patent application filed for poly-GA vaccination targeting C9orf72 ALS/FTD. C.H. is the chief consultant of ISAR Bioscience.

References

Afgan E, Baker D, Batut B, van den Beek M, Bouvier D, Cech M, Chilton J, Clements D, Coraor N, Grunin BA et al (2018) The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. *Nucleic Acids Res* 46: W537–W544

Albert M, Maitre-Coello G, Danis C, Leger S, Caillieres R, Carrier S, Skrobala E, Landrieu I, Michel A, Schmitt M et al (2019) Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody. *Brain* 142: 1736–1750

Ash PE, Bieniek KF, Gendron TF, Caulfield T, Lin WL, Dejesus-Hernandez M, van Blitterswijk MM, Jansen-West K, Paul JW III, Rademakers R et al (2013) Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. *Neuron* 77: 639–646

Asuni AA, Boutajangout A, Quarterman D, Sigurdsson EM (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. *J Neurosci* 27: 9115–9129

Atanasiu A, Decman V, White D, Ramos M, Ikiz B, Lee HC, Siao CJ, Brydges S, LaRosa E, Bai Y (2016) C9ORF72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice. *Sci Rep* 6: 23204

Axelsen TV, Holm A, Christiansen G, Birkeland S (2011) Identification of the shortest Abeta-peptide generating highly specific antibodies against the C-terminal end of amyloid-beta42. *Vaccine* 29: 3260–3269

Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H (2010) Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. *Exp Neurol* 224: 472–485

Chang YJ, Jeng US, Chiang YL, Hwang IS, Chen YR (2017) Differential effects of immunotherapy with antibodies targeting alpha-synuclein oligomers and fibrils in a transgenic model of synucleinopathy. *Neurobiol Dis* 104: 85–96

Fenberg E, Oeckl P, Steinacker P, Verde F, Barro C, Van Damme P, Gray E, Grosskreutz J, Jardel C, Kuhle J et al (2018) Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. *Neurology* 90: e22–e30

Frick P, Seller C, Mackenzie IRA, Cheng CY, Tahraoui-Bories J, Martinat C, Pasterkamp RJ, Prudlo J, Edbauer D, Oulad-Abdelghani M et al (2018) Novel antibodies reveal presynaptic localization of C9orf72 protein and reduced protein levels in C9orf72 mutation carriers. *Acta Neuropathol Commun* 6: 72

Games D, Valera E, Spencer B, Rockenstein E, Mante A, Adame A, Patrick C, Ubbi K, Nuber S, Sacayon P et al (2014) Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson’s disease-like models. *J Neurosci* 34: 9441–9454

Gendron TF, Chew J, Stankowski JN, Hayes LR, Zhang YJ, Prudencio M, Carlonlogo Y, Daughrity LM, Jansen-West K, Perkerson EA et al (2017) Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. *Sci Transl Med* 9: eaai7866

Heindl S, Cesierich B, Benakis C, Lloversa L, Duering M, Liesa A (2018) Automated morphological analysis of microglia after stroke. *Front Cell Neurosci* 12: 106

Jadhav S, Avila J, Scholl M, Kovacs GG, Kovari E, Skrabania E, van den Beek M, Constable R, El-Agnaf O, Overk C, Rockenstein E, Mante M, Adame A, Vaikath N, Majbour N, Lee SJ, Kim C et al (2017) Poly-GA vaccination targeting alpha-synuclein oligomers and fibrils in a transgenic model of synucleinopathy. *Neurobiol Dis* 104: 85–96

Kontsekova E, Malawska B, de Silva R et al (2019) A walk through tau therapeutic strategies. *Acta Neuropathol Commun* 7: 22

Jiang J, Zhu Q, Gendron TF, Saberi S, McAlonis-Dowmes M, Seelam A, Stauffer JE, Jafar-Nejad P, Drenner K, Schulte D et al (2016) Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 is alleviated by antisenes oligonucleotides targeting GGGGCC-containing RNAs. *Neuron* 90: 535–550

Khali M, Teunissen CE, Otto M, Piehl F, Sormani MP, Catringer T, Barro C, Kappos L, Comabella M, Fazekas F et al (2018) Neurofilaments as biomarkers in neurological disorders. *Nat Rev Neurol* 14: 577–589

Khosravi B, Hartmann M, May S, Mohl C, Ederle H, Michaelens M, Schludi MH, Dornmann D, Edbauer D (2017) Cytoplasmic poly-GA aggregates impair nuclear import of TDP-43 in C9orf72 ALS/FTLD. *Hum Mol Genet* 26: 790–801

Kontsekova E, Zilka N, Kovaceich B, Novak P, Novak M (2014) First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model. *Alzheimers Res Ther* 6: 44

Kverneland AH, Enevold C, Donia M, Bastholt L, Svane IM, Nielsen CH (2018) Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab. *Oncoimmunology* 7: e1424674

Landen JW, Cohen S, Billing CB Jr, Cronenberger C, Styrren S, Burstin AH, Sattler C, Lee JH, Jack CR Jr, Kantarci K et al (2017) Multiple-dose ponezumab for mild-to-moderate Alzheimer’s disease: safety and efficacy. *Alzheimers Dement* (N Y) 3: 339–347

Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, Griffith SG, Black RS, Schenk D, Seubert P (2005) Abeta42 immunization in Alzheimer’s disease generates Abeta N-terminal antibodies. *Ann Neurol* 58: 430–435

Lee YB, Baskaran P, Gomez-Deza J, Chen HJ, Nishimura AL, Smith BN, Troakes C, Adachi Y, Stepto A, Petrucelli L et al (2017) C9orf72 poly GA RAN-translated protein plays a key role in amyotrophic lateral sclerosis via aggregation and toxicity. *Hum Mol Genet* 26: 4765–4777
Novak P, Schmidt R, Kontsevova E, Kovacech B, Smolek T, Katina S, Fialova L, Pricina M, Parrak V, Dal-Bianco P et al (2018b) FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease. *Alzheimers Res Ther* 10: 108

Orogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S et al (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. *Neurology* 61: 46 – 54

R Core Team (2018) *R: a language and environment for statistical computing*. Vienna, Austria: R Foundation for Statistical Computing. https://www.R-project.org/

Rajamohamedsait H, Rasool S, Rajamohamedsait W, Lin Y, Sigurdsson EM (2017) Prophylactic active tau immunization leads to sustained reduction in both tau and amyloid-β pathologies in 3xTg mice. *Sci Rep* 7: 17034

Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L et al (2011) A hexanucleotide repeat expansion in C9orf72 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron* 72: 257 – 268

Schelle J, Hasler LM, Copfert JC, joos TO, Vanderstichele H, Stoops E, Mandelkow EM, Neumann U, Shimsheer DA, Staufenbiiel M et al (2017) Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition. *Alzheimers Dement* 13: 701 – 709

Schenk D, Barbour R, Dunn W, Gordon C, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K et al (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. *Nature* 400: 173 – 177

Schludi MH, May S, Grasser FA, Rentzsch K, Kremmer E, Kupper C, Klopotock T, German Consortium for Frontotemporal Lobar Degeneration, Bavarian Brain Banking Alliance, Arzberger T et al (2015) Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing. *Acta Neuropathol* 130: 537 – 555

Schludi MH, Becker L, Garrett L, Gendron TF, Zhou Q, Schreiber F, Popper B, Dimo L, Strom TM, Winkelmann J et al (2017) Spinal poly-GA inclusions in a C9orf72 mouse model trigger motor deficits and inflammation without neuron loss. *Acta Neuropathol* 134: 241 – 254

Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maior M, Dunstan R, Salloway S, Chen T, Ling Y et al (2016) The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease. *Nature* 537: 50 – 56

Shu J, Fu H, Qiu G, Kaye P, Ilyas M (2013) Segmenting overlapping cell nuclei in digital histopathology images. In 2013 35th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). pp 5445 – 5448.

Swarup V, Phaneuf D, Dupre N, Petri S, Strong M, Kriz J, Julien JP (2011) Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor kappaB-mediated pathogenic pathways. *J Exp Med* 208: 2429 – 2447

Truett GE, Heeger P, Mynatt RL, Truett AA, Walker JA, Warman ML (2000) Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). *Biotecniques* 29: 52, 54

Vatsavaiy SC, Yoon SJ, Gardner RC, Gendron TF, Vargas JN, Trujillo A, Pribadi M, Phillips JJ, Gaus SE, Hixon JD et al (2016) Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia. *Brain* 139: 3202 – 3216

Westergard T, Jensen BK, Wen X, Cai J, Kropf E, Iacovitti L, Pasinelli P, Trotti D, Schludi MH, Neumann U, Shimshek DA, Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maior M, Dunstan R, Salloway S, Chen T, Ling Y et al (2016) The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease. *Nature* 537: 50 – 56

Yanamandra K, Kloufy N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM (2013) Anti-tau antibodies that block tau
aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80: 402–414
Yu G, Wang LG, Han Y, He QY (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16: 284–287
Yu YJ, Atwal JK, Zhang Y, Tong RK, Wildsmith KR, Tan C, Bien-Ly N, Hersom M, Maloney JA, Meilandt WJ et al (2014) Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Sci Transl Med 6: 261ra154
Zhang YJ, Gendron TF, Grima JC, Sasaguri H, Jansen-West K, Xu YF, Katzman RB, Gass J, Murray ME, Shinohara M et al (2016) C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nat Neurosci 19: 668–677
Zhao W, Beers DR, Bell S, Wang J, Wen S, Baloh RH, Appel SH (2015) TDP-43 activates microglia through NF-kappaB and NLRP3 inflammasome. Exp Neurol 273: 24–35
Zhou Q, Lehmer C, Michaelsen M, Mori K, Altermange D, Baumjohann D, Schludi MH, Greiling J, Farny D, Flatley A et al (2017) Antibodies inhibit transmission and aggregation of C9orf72 poly-GA dipeptide repeat proteins. EMBO Mol Med 9: 687–702

License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.